<DOC>
	<DOCNO>NCT00196053</DOCNO>
	<brief_summary>The purpose observational registry collect continuum meaningful clinical data ARCHIMEDES implantable pump pain management</brief_summary>
	<brief_title>The Effectiveness Pain Management Using ARCHIMEDESÂ® Constant-Flow Infusion Pump System Intrathecal Delivery</brief_title>
	<detailed_description>Pain management long-standing challenge medical community , specifically treatment chronic pain . Chronic Pain define American Chronic Pain Association `` pain continue month beyond usual recovery period illness injury pain go month year result chronic condition . '' Chronic pain affect patient 's quality life , work performance attendance , mental health , social interaction overall activity daily live . Implantable pump use cancer non-cancer patient , pain , resistant conventional therapy . Intrathecal morphine administration accept safe effective method control reduce pain impact sufferer . The Codman ARCHIMEDES Implantable Constant-Flow Infusion Pump CE mark , commercially available Europe intrathecal delivery morphine baclofen since August 1997 . ARCHIMEDES intend treatment chronic intractable ( cancer non-cancer ) pain , require chronic intrathecal infusion preservative-free morphine sulfate . This European , multicenter , prospective , single arm , observational registry conduct total 150 Subjects 10 center Europe . Subjects follow 3 , 6 , 9 , 12 month post Archimedes implant ass pain management quality life .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>The Subject suffering chronic ( benign and/or malignant ) intractable pain least 2 month duration ( pending national law ) preimplant value equal 7 Visual Analog Pain Scale . The subject tolerate oral pain medication require therapeutic dose treat his/her pain . The Subject minimum reasonable life expectancy least 6 month . The Subject give write Informed Consent prior enrollment study . The body size Subject sufficient accept pump bulk weight , per Principal Investigator 's discretion . The Subject willing participate registry 1 year post implant willing comply investigational plan requirement . It Principal Investigator 's judgment , base knowledge Subject , Subject 's condition , well feature implantable system Subject appropriate candidate pain management utilize implantable pump continuously deliver preservativefree morphine sulfate via intrathecal route . The Subject skin condition ( i.e. , scleroderma , psoriasis , rash , open wound ) site choose implantation would compromise integrity access injection port . The Subject previously enrol participated investigational drug device trial within precede 4 week . The Subject know contraindication preservativefree morphine sulfate . The Subject suspect documented allergy preservativefree morphine sulfate relate drug . The Subject suspect documented allergy material infusion pump catheter ( ) ( example , silicone ) . The Subject history drug and/or alcohol abuse per Principal Investigator discretion . The Subject female pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Intrathecal pain management</keyword>
	<keyword>constant flow pump</keyword>
</DOC>